Myeloid-derived suppressor cells: Therapeutic modulation in cancer

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 3, 2012, Pages 838-855

  Wilcox, Ryan A ^a,b  

^a Division of Hematology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Arginase; B7 H1; Cytokine; Myeloid derived suppressor cell; Nitric oxide synthase; Review; T cell

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; BEVACIZUMAB; CANCER VACCINE; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE B; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; NIFUROXAZIDE; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; SILDENAFIL; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; STEM CELL FACTOR; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MULTIPLE MYELOMA; MYELOID DERIVED SUPPRESSOR CELL; MYELOPOIESIS; NONHUMAN; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; BONE MARROW CELL; CYTOLOGY; NEOPLASM; PATHOLOGY; REVIEW;

BONE MARROW CELLS; HUMANS; NEOPLASMS;

EID: 84860852693     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e423     Document Type: Article

References (211)

1. F. Balkwill and A. Mantovani: Inflammation and cancer: back to Virchow? Lancet, 357(9255), 539-45 (2001) (Pubitemid 32173595)
2. A. Mantovani, P. Allavena, A. Sica and F. Balkwill: Cancer-related inflammation. Nature, 454(7203), 436-44 (2008)
3. G. P. Dunn, L. J. Old and R. D. Schreiber: The three Es of cancer immunoediting. Annu Rev Immunol, 22, 329-60 (2004) (Pubitemid 38680426)
4. T. F. Gajewski, Y. Meng and H. Harlin: Immune suppression in the tumor microenvironment. J Immunother, 29(3), 233-40 (2006) (Pubitemid 44297291)
5. S. A. Rosenberg, J. C. Yang and N. P. Restifo: Cancer immunotherapy: moving beyond current vaccines. Nat Med, 10(9), 909-15 (2004) (Pubitemid 39273730)
6. G. A. Rabinovich, D. Gabrilovich and E. M. Sotomayor: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol, 25, 267-96 (2007) (Pubitemid 46697910)
7. J. Turkson, T. Bowman, R. Garcia, E. Caldenhoven, R. P. De Groot and R. Jove: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Molecular & Cellular Biology, 18(5), 2545-52 (1998) (Pubitemid 28183424)
8. J. F. Bromberg, C. M. Horvath, D. Besser, W. W. Lathem and J. E. Darnell, Jr.: Stat3 activation is required for cellular transformation by v-src. Molecular & Cellular Biology, 18(5), 2553-8 (1998) (Pubitemid 28183425)
9. J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese and J. E. Darnell, Jr.: Stat3 as an oncogene.[erratum appears in Cell 1999 Oct 15;99(2):239]. Cell, 98(3), 295-303 (1999) (Pubitemid 29380565)
10. C. L. Yu, D. J. Meyer, G. S. Campbell, A. C. Larner, C. Carter-Su, J. Schwartz and R. Jove: Enhanced DNAbinding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science, 269(5220), 81-3 (1995)
11. S. Nabarro, N. Himoudi, A. Papanastasiou, K. Gilmour, S. Gibson, N. Sebire, A. Thrasher, M. P. Blundell, M. Hubank, G. Canderan and J. Anderson: Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. Journal of Experimental Medicine, 202(10), 1399-410 (2005) (Pubitemid 41668742)
12. Z. Zhong, Z. Wen and J. E. Darnell, Jr.: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 264(5155), 95-8 (1994) (Pubitemid 24144493)
13. K. English, J. M. Ryan, L. Tobin, M. J. Murphy, F. P. Barry and B. P. Mahon: Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol, 156(1), 149-60 (2009)
14. S. H. Yang, M. J. Park, I. H. Yoon, S. Y. Kim, S. H. Hong, J. Y. Shin, H. Y. Nam, Y. H. Kim, B. Kim and C. G. Park: Soluble mediators from mesenchymal stem cells suppressT cell proliferation by inducing IL-10. Exp Mol Med, 41(5), 315-24 (2009)
15. T. Silzle, G. J. Randolph, M. Kreutz and L. A. Kunz-Schughart: The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer, 108(2), 173-80 (2004) (Pubitemid 37541767)
16. J. K. Mulligan, D. M. Lathers and M. R. Young: Tumors skew endothelial cells to disrupt NK cell, T-cell and macrophage functions. Cancer Immunol Immunother, 57(7), 951-61 (2008)
17. A. Wasiuk, V. C. de Vries, K. Hartmann, A. Roers and R. J. Noelle: Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol, 155(2), 140-6 (2009)
18. R. M. Steinman, D. Hawiger and M. C. Nussenzweig: Tolerogenic dendritic cells. Annu Rev Immunol, 21, 685-711 (2003) (Pubitemid 37174545)
19. A. J. Muller, M. D. Sharma, P. R. Chandler, J. B. Duhadaway, M. E. Everhart, B. A. Johnson, 3rd, D. J. Kahler, J. Pihkala, A. P. Soler, D. H. Munn, G. C. Prendergast and A. L. Mellor: Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A, 105(44), 17073-8 (2008)
20. A. Mantovani, S. Sozzani, M. Locati, P. Allavena and A. Sica: Macrophage polarization: tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol, 23(11), 549-55 (2002) (Pubitemid 35223554)
21. M. Terabe and J. A. Berzofsky: The role of NKT cells in tumor immunity. Adv Cancer Res, 101, 277-348 (2008)
22. M. Terabe and J. A. Berzofsky: NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol, 28(11), 491-6 (2007) (Pubitemid 350087811)
23. G. Peng, H. Y. Wang, W. Peng, Y. Kiniwa, K. H. Seo and R. F. Wang: Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity, 27(2), 334-48 (2007) (Pubitemid 47284914)
24. E. M. Shevach: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity, 30(5), 636-45 (2009)
25. M. R. Young, M. Newby and H. T. Wepsic: Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res, 47(1), 100-5 (1987) (Pubitemid 17002105)
26. M. R. Young, N. K. Ellis, M. E. Young and H. T. Wepsic: Stimulation of hematopoiesis and bone marrow suppressor cells by the subcutaneous injection of linoleic acid. Cell Immunol, 107(1), 238-48 (1987) (Pubitemid 17088608)
27. L. P. Seung, D. A. Rowley, P. Dubey and H. Schreiber: Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A, 92(14), 6254-8 (1995)
28. D. I. Gabrilovich, V. Bronte, S. H. Chen, M. P. Colombo, A. Ochoa, S. Ostrand-Rosenberg and H. Schreiber: The terminology issue for myeloid-derived suppressor cells. Cancer Res, 67(1), 425; author reply 426 (2007) (Pubitemid 46142802)
29. D. I. Gabrilovich and S. Nagaraj: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 9(3), 162-74 (2009)
30. J. I. Youn, S. Nagaraj, M. Collazo and D. I. Gabrilovich: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol, 181(8), 5791-802 (2008)
31. N. Umemura, M. Saio, T. Suwa, Y. Kitoh, J. Bai, K. Nonaka, G. F. Ouyang, M. Okada, M. Balazs, R. Adany, T. Shibata and T. Takami: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-And M2-Type characteristics. J Leukoc Biol, 83(5), 1136-44 (2008) (Pubitemid 351960345)
32. B. Huang, P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino and S. H. Chen: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and Tcell anergy in tumor-bearing host. Cancer Res, 66(2), 1123-31 (2006) (Pubitemid 43165981)
33. R. Yang, Z. Cai, Y. Zhang, W. H. t. Yutzy, K. F. Roby and R. B. Roden: CD80 in immune suppression by mouse ovarian carcinoma-Associated Gr-1+CD11b+ myeloid cells. Cancer Res, 66(13), 6807-15 (2006) (Pubitemid 44085641)
34. K. Movahedi, M. Guilliams, J. Van Den Bossche, R. Van Den Bergh, C. Gysemans, A. Beschin, P. De Baetselier and J. A. Van Ginderachter: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood, 111(8), 4233-44 (2008)
35. V. Greifenberg, E. Ribechini, S. Rossner and M. B. Lutz: Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol, 39(10), 2865-76 (2009)
36. L. Dolcetti, E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa, M. Geilich, G. Winkels, E. Traggiai, A. Casati, F. Grassi and V. Bronte: Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol, 40(1), 22-35)
37. A. C. Ochoa, A. H. Zea, C. Hernandez and P. C. Rodriguez: Arginase, prostaglandins, and myeloidderived suppressor cells in renal cell carcinoma. Clin Cancer Res, 13(2 Pt 2), 721s-726s (2007)
38. B. Almand, J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone and D. I. Gabrilovich: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol, 166(1), 678-89 (2001) (Pubitemid 32038493)
39. A. H. Zea, P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, J. Mier and A. C. Ochoa: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Research, 65(8), 3044-8 (2005) (Pubitemid 40524582)
40. J. Schmielau and O. J. Finn: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res, 61(12), 4756-60 (2001) (Pubitemid 32691887)
41. P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani and L. Rivoltini: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocytemacrophage colony-stimulation factor-based antitumor vaccine.[see comment]. Journal of Clinical Oncology, 25(18), 2546-53 (2007) (Pubitemid 47041228)
42. B. Hoechst, L. A. Ormandy, M. Ballmaier, F. Lehner, C. Kruger, M. P. Manns, T. F. Greten and F. Korangy: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology, 135(1), 234-43 (2008) (Pubitemid 351899008)
43. P. C. Rodriguez, M. S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, R. Sierra and A. C. Ochoa: Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res, 69(4), 1553-60 (2009)
44. R. A. Wilcox, A. L. Feldman, D. A. Wada, Z. Z. Yang, N. I. Comfere, H. Dong, E. D. Kwon, A. J. Novak, S. N. Markovic, M. R. Pittelkow, T. E. Witzig and S. M. Ansell: B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood, 114(10), 2149-58 (2009)
45. I. Marigo, L. Dolcetti, P. Serafini, P. Zanovello and V. Bronte: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev, 222, 162-79 (2008) (Pubitemid 351430364)
46. L. A. Haile, R. von Wasielewski, J. Gamrekelashvili, C. Kruger, O. Bachmann, A. M. Westendorf, J. Buer, R. Liblau, M. P. Manns, F. Korangy and T. F. Greten: Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology, 135(3), 871-81, 881 e1-5 (2008)
47. S. Kusmartsev, S. Nagaraj and D. I. Gabrilovich: Tumorassociated CD8+ T cell tolerance induced by bone marrowderived immature myeloid cells. J Immunol, 175(7), 4583-92 (2005) (Pubitemid 41361997)
48. P. Sinha, C. Okoro, D. Foell, H. H. Freeze, S. Ostrand-Rosenberg and G. Srikrishna: Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol, 181(7), 4666-75 (2008)
49. D. Ilkovitch and D. M. Lopez: The liver is a site for tumorinduced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res, 69(13), 5514-21 (2009)
50. P. Serafini, R. Carbley, K. A. Noonan, G. Tan, V. Bronte and I. Borrello: High-dose granulocyte-macrophage colonystimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res, 64(17), 6337-43 (2004) (Pubitemid 39129439)
51. A. Satoh, T. Miura, K. Satoh, A. Masamune, T. Yamagiwa, Y. Sakai, K. Shibuya, K. Takeda, M. Kaku and T. Shimosegawa: Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis. Pancreas, 25(3), 245-50 (2002)
52. M. J. Delano, P. O. Scumpia, J. S. Weinstein, D. Coco, S. Nagaraj, K. M. Kelly-Scumpia, K. A. O'Malley, J. L. Wynn, S. Antonenko, S. Z. Al-Quran, R. Swan, C. S. Chung, M. A. Atkinson, R. Ramphal, D. I. Gabrilovich, W. H. Reeves, A. Ayala, J. Phillips, D. Laface, P. G. Heyworth, M. Clare-Salzler and L. L. Moldawer: MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med, 204(6), 1463-74 (2007) (Pubitemid 46919883)
53. B. Zhu, Y. Bando, S. Xiao, K. Yang, A. C. Anderson, V. K. Kuchroo and S. J. Khoury: CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol, 179(8), 5228-37 (2007)
54. M. B. Voisin, D. Buzoni-Gatel, D. Bout and F. Velge-Roussel: Both expansion of regulatory GR1+ CD11b+ myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung-Associated immune system during acute toxoplasmosis. Infect Immun, 72(9), 5487-92 (2004)
55. W. K. Nevala, C. M. Vachon, A. A. Leontovich, C. G. Scott, M. A. Thompson and S. N. Markovic: Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res, 15(6), 1931-9 (2009)
56. P. Lissoni, F. Malugani, A. Bonfanti, R. Bucovec, S. Secondino, F. Brivio, A. Ferrari-Bravo, R. Ferrante, L. Vigore, F. Rovelli, M. Mandala, S. Viviani, L. Fumagalli and G. S. Gardani: Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents, 15(2), 140-4 (2001) (Pubitemid 32717550)
57. M. Groblewska, B. Mroczko, U. Wereszczynska-Siemiatkowska, P. Mysliwiec, B. Kedra and M. Szmitkowski: Serum levels of granulocyte colonystimulating factor (G-CSF) and macrophage colonystimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med, 45(1), 30-4 (2007)
58. J. Kaminska, M. Kowalska, B. Kotowicz, M. Fuksiewicz, M. Glogowski, E. Wojcik, M. Chechlinska and J. Steffen: Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF -An independent prognostic factor. Oncology, 70(2), 115-25 (2006) (Pubitemid 43760337)
59. Z. A. Dehqanzada, C. E. Storrer, M. T. Hueman, R. J. Foley, K. A. Harris, Y. H. Jama, C. D. Shriver, S. Ponniah and G. E. Peoples: Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep, 17(3), 687-94 (2007)
60. J. Kaminska, M. P. Nowacki, M. Kowalska, A. Rysinska, M. Chwalinski, M. Fuksiewicz, W. Michalski and M. Chechlinska: Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I-An independent prognostic factor. Tumour Biol, 26(4), 186-94 (2005) (Pubitemid 41379744)
61. M. M. Taketo: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst, 90(20), 1529-36 (1998)
62. M. M. Taketo: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst, 90(21), 1609-20 (1998)
63. J. E. Talmadge, K. C. Hood, L. C. Zobel, L. R. Shafer, M. Coles and B. Toth: Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol, 7(2), 140-51 (2007) (Pubitemid 46043318)
64. P. Sinha, V. K. Clements, A. M. Fulton and S. Ostrand-Rosenberg: Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res, 67(9), 4507-13 (2007) (Pubitemid 46815102)
65. P. C. Rodriguez, C. P. Hernandez, D. Quiceno, S. M. Dubinett, J. Zabaleta, J. B. Ochoa, J. Gilbert and A. C. Ochoa: Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med, 202(7), 931-9 (2005) (Pubitemid 41396893)
66. P. Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino and S. H. Chen: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood, 111(1), 219-28 (2008)
67. C. Menetrier-Caux, G. Montmain, M. C. Dieu, C. Bain, M. C. Favrot, C. Caux and J. Y. Blay: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 92(12), 4778-91 (1998) (Pubitemid 29005881)
68. R. Eager and J. Nemunaitis: GM-CSF gene-Transduced tumor vaccines. Molecular Therapy: the Journal of the American Society of Gene Therapy, 12(1), 18-27 (2005) (Pubitemid 40862352)
69. G. Parmiani, C. Castelli, L. Pilla, M. Santinami, M. P. Colombo and L. Rivoltini: Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Annals of Oncology, 18(2), 226-32 (2007) (Pubitemid 46323086)
70. M. A. Guthridge, J. A. Powell, E. F. Barry, F. C. Stomski, B. J. McClure, H. Ramshaw, F. A. Felquer, M. Dottore, D. T. Thomas, B. To, C. G. Begley and A. F. Lopez: Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO Journal, 25(3), 479-89 (2006) (Pubitemid 43237655)
71. T. R. Hercus, D. Thomas, M. A. Guthridge, P. G. Ekert, J. King-Scott, M. W. Parker and A. F. Lopez: The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood, 114(7), 1289-98 (2009)
72. M. A. Guthridge, J. A. Powell, E. F. Barry, F. C. Stomski, B. J. McClure, H. Ramshaw, F. A. Felquer, M. Dottore, D. T. Thomas, B. To, C. G. Begley and A. F. Lopez: Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. Embo J, 25(3), 479-89 (2006) (Pubitemid 43237655)
73. T. Garrity, R. Pandit, M. A. Wright, J. Benefield, S. Keni and M. R. Young: Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. International Journal of Cancer, 73(5), 663-9 (1997) (Pubitemid 127483061)
74. L. Pilla, R. Patuzzo, L. Rivoltini, M. Maio, E. Pennacchioli, E. Lamaj, A. Maurichi, S. Massarut, A. Marchiano, C. Santantonio, D. Tosi, F. Arienti, A. Cova, G. Sovena, A. Piris, D. Nonaka, I. Bersani, A. Di Florio, M. Luigi, P. K. Srivastava, A. Hoos, M. Santinami and G. Parmiani: A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-Alpha in metastatic melanoma patients. Cancer Immunology, Immunotherapy, 55(8), 958-68 (2006) (Pubitemid 43673585)
75. F. Belli, A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, M. Carrabba, G. Scita, C. Santantonio, L. Pilla, G. Tragni, C. Lombardo, F. Arienti, A. Marchiano, P. Queirolo, F. Bertolini, A. Cova, E. Lamaj, L. Ascani, R. Camerini, M. Corsi, N. Cascinelli, J. J. Lewis, P. Srivastava and G. Parmiani: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.[see comment][erratum appears in J Clin Oncol 2002 Dec 1;20(23):4610]. Journal of Clinical Oncology, 20(20), 4169-80 (2002) (Pubitemid 35191019)
76. B. Mroczko, M. Szmitkowski, U. Wereszczynska-Siemiatkowska and G. Jurkowska: Hematopoietic cytokines in the sera of patients with pancreatic cancer. Clinical Chemistry & Laboratory Medicine, 43(2), 146-50 (2005) (Pubitemid 40361460)
77. B. Mroczko, M. Szmitkowski, B. Okulczyk and Z. Piotrowski: Granulocyte-macrophage-colony stimulating factor in patients with colorectal cancer. Folia Histochemica et Cytobiologica, 39 Suppl 2, 110-1 (2001) (Pubitemid 34070782)
78. F. Abe, A. J. Dafferner, M. Donkor, S. N. Westphal, E. M. Scholar, J. C. Solheim, R. K. Singh, T. A. Hoke and J. E. Talmadge: Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother (2009)
79. Z. F. Vasconcelos, B. M. Dos Santos, J. Farache, T. S. Palmeira, R. B. Areal, J. M. Cunha, M. A. Barcinski and A. Bonomo: G-CSF-Treated granulocytes inhibit acute graft-versus-host disease. Blood, 107(5), 2192-9 (2006) (Pubitemid 43289406)
80. W. I. Bensinger, C. H. Weaver, F. R. Appelbaum, S. Rowley, T. Demirer, J. Sanders, R. Storb and C. D. Buckner: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood, 85(6), 1655-8 (1995)
81. N. Schmitz, P. Dreger, M. Suttorp, E. B. Rohwedder, T. Haferlach, H. Loffler, A. Hunter and N. H. Russell: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood, 85(6), 1666-72 (1995)
82. Z. S. Pavletic, M. R. Bishop, S. R. Tarantolo, S. Martin-Algarra, P. J. Bierman, J. M. Vose, E. C. Reed, T. G. Gross, J. Kollath, K. Nasrati, J. D. Jackson, J. O. Armitage and A. Kessinger: Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol, 15(4), 1608-16 (1997) (Pubitemid 27167400)
83. M. Mielcarek, P. J. Martin and B. Torok-Storb: Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood, 89(5), 1629-34 (1997) (Pubitemid 27097456)
84. M. Mielcarek, L. Graf, G. Johnson and B. Torok-Storb: Production of interleukin-10 by granulocyte colonystimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood, 92(1), 215-22 (1998) (Pubitemid 28303195)
85. D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf and D. P. Carbone: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92(11), 4150-66 (1998) (Pubitemid 28544331)
86. D. I. Gabrilovich, H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh and D. P. Carbone: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.[erratum appears in Nat Med 1996 Nov;2(11):1267]. Nature Medicine, 2(10), 1096-103 (1996) (Pubitemid 26338628)
87. Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang and D. P. Carbone: Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood, 110(2), 624-31 (2007) (Pubitemid 47105401)
88. B. Larrivee, I. Pollet and A. Karsan: Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocytemacrophage colony-stimulating factor. Journal of Immunology, 175(5), 3015-24 (2005) (Pubitemid 41170520)
89. D. Foell, H. Wittkowski, T. Vogl and J. Roth: S100 proteins expressed in phagocytes: a novel group of damageassociated molecular pattern molecules. Journal of Leukocyte Biology, 81(1), 28-37 (2007) (Pubitemid 46021248)
90. P. Cheng, C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, J. Roth and D. I. Gabrilovich: Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med, 205(10), 2235-49 (2008)
91. S. K. Bunt, P. Sinha, V. K. Clements, J. Leips and S. Ostrand-Rosenberg: Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology, 176(1), 284-90 (2006) (Pubitemid 43023273)
92. S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips and S. Ostrand-Rosenberg: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloidderived suppressor cells and limits tumor progression. Cancer Research, 67(20), 10019-26 (2007)
93. X. Song, Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov and R. N. Apte: CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. Journal of Immunology, 175(12), 8200-8 (2005) (Pubitemid 41798384)
94. S. Tu, G. Bhagat, G. Cui, S. Takaishi, E. A. Kurt-Jones, B. Rickman, K. S. Betz, M. Penz-Oesterreicher, O. Bjorkdahl, J. G. Fox and T. C. Wang: Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell, 14(5), 408-19 (2008)
95. J. A. Lust, M. Q. Lacy, S. R. Zeldenrust, A. Dispenzieri, M. A. Gertz, T. E. Witzig, S. Kumar, S. R. Hayman, S. J. Russell, F. K. Buadi, S. M. Geyer, M. E. Campbell, R. A. Kyle, S. V. Rajkumar, P. R. Greipp, M. P. Kline, Y. Xiong, L. L. Moon-Tasson and K. A. Donovan: Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc, 84(2), 114-22 (2009)
96. P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte and I. Borrello: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloidderived suppressor cell function. Journal of Experimental Medicine, 203(12), 2691-702 (2006) (Pubitemid 44833345)
97. J. E. Darnell, I. M. Kerr and G. R. Stark: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264(5164), 1415-21 (1994) (Pubitemid 24217131)
98. T. Taga and T. Kishimoto: Gp130 and the interleukin-6 family of cytokines. Annual Review of Immunology, 15, 797-819 (1997) (Pubitemid 27169299)
99. H. Yu, M. Kortylewski and D. Pardoll: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews. Immunology, 7(1), 41-51 (2007) (Pubitemid 46020826)
100. M. Kortylewski and H. Yu: Role of Stat3 in suppressing anti-Tumor immunity. Current Opinion in Immunology, 20(2), 228-33 (2008)
101. G. Niu, K. L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang, T. Wang, D. Sinibaldi, D. Coppola, R. Heller, L. M. Ellis, J. Karras, J. Bromberg, D. Pardoll, R. Jove and H. Yu: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 21(13), 2000-8 (2002) (Pubitemid 34270888)
102. Q. Xu, J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G. L. Semenza, J. Q. Cheng, R. Jove and H. Yu: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene, 24(36), 5552-60 (2005) (Pubitemid 43119350)
103. D. Wei, X. Le, L. Zheng, L. Wang, J. A. Frey, A. C. Gao, Z. Peng, S. Huang, H. Q. Xiong, J. L. Abbruzzese and K. Xie: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 22(3), 319-29 (2003) (Pubitemid 36194328)
104. H. Sumimoto, F. Imabayashi, T. Iwata and Y. Kawakami: The BRAF-MAPK signaling pathway is essential for cancerimmune evasion in human melanoma cells. Journal of Experimental Medicine, 203(7), 1651-6 (2006) (Pubitemid 44036269)
105. I. Kinjyo, H. Inoue, S. Hamano, S. Fukuyama, T. Yoshimura, K. Koga, H. Takaki, K. Himeno, G. Takaesu, T. Kobayashi and A. Yoshimura: Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. Journal of Experimental Medicine, 203(4), 1021-31 (2006)
106. Y. Nefedova, S. Nagaraj, A. Rosenbauer, C. Muro-Cacho, S. M. Sebti and D. I. Gabrilovich: Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-Activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research, 65(20), 9525-35 (2005) (Pubitemid 41508023)
107. Y. Nefedova, M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove and D. Gabrilovich: Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. Journal of Immunology, 172(1), 464-74 (2004) (Pubitemid 38020502)
108. M. Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mule, W. G. Kerr, R. Jove, D. Pardoll and H. Yu: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine, 11(12), 1314-21 (2005) (Pubitemid 41752912)
109. T. Wang, G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, W. Dalton, R. Jove, D. Pardoll and H. Yu: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.[erratum appears in Nat Med. 2004 Feb;10(2):209]. Nature Medicine, 10(1), 48-54 (2004) (Pubitemid 38524698)
110. S. Kusmartsev and D. I. Gabrilovich: STAT1 signaling regulates tumor-Associated macrophagemediated T cell deletion. J Immunol, 174(8), 4880-91 (2005)
111. P. Sinha, V. K. Clements and S. Ostrand-Rosenberg: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol, 174(2), 636-45 (2005) (Pubitemid 40094255)
112. P. Sinha, V. K. Clements, S. Miller and S. Ostrand-Rosenberg: Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother, 54(11), 1137-42 (2005) (Pubitemid 41396817)
113. Y. Liu, Y. Yu, S. Yang, B. Zeng, Z. Zhang, G. Jiao, Y. Zhang, L. Cai and R. Yang: Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother, 58(5), 687-97 (2009)
114. Y. Liu, B. Zeng, Z. Zhang, Y. Zhang and R. Yang: B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol, 129(3), 471-81 (2008)
115. T. Azuma, S. Yao, G. Zhu, A. S. Flies, S. J. Flies and L. Chen: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 111(7), 3635-43 (2008)
116. L. Wang, K. Pino-Lagos, V. C. de Vries, I. Guleria, M. H. Sayegh and R. J. Noelle: Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 105(27), 9331-6 (2008)
117. J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont and B. Quesnel: Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, 110(1), 296-304 (2007) (Pubitemid 47026847)
118. P. Loke and J. P. Allison: PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A, 100(9), 5336-41 (2003) (Pubitemid 36542706)
119. A. Y. Gong, R. Zhou, G. Hu, X. Li, P. L. Splinter, S. P. O'Hara, N. F. LaRusso, G. A. Soukup, H. Dong and X. M. Chen: MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol, 182(3), 1325-33 (2009)
120. D. I. Gabrilovich, M. P. Velders, E. M. Sotomayor and W. M. Kast: Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. Journal of Immunology, 166(9), 5398-406 (2001) (Pubitemid 32374159)
121. S. Nagaraj, K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. Schneck and D. I. Gabrilovich: Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med, 13(7), 828-35 (2007) (Pubitemid 47038194)
122. S. Ekmekcioglu, J. Ellerhorst, C. M. Smid, V. G. Prieto, M. Munsell, A. C. Buzaid and E. A. Grimm: Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res, 6(12), 4768-75 (2000) (Pubitemid 32110418)
123. Y. Nakamura, H. Yasuoka, M. Tsujimoto, K. Yoshidome, M. Nakahara, K. Nakao, M. Nakamura and K. Kakudo: Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res, 12(4), 1201-7 (2006) (Pubitemid 43342509)
124. B. G. Bentz, G. K. Haines, 3rd and J. A. Radosevich: Increased protein nitrosylation in head and neck squamous cell carcinogenesis. Head Neck, 22(1), 64-70 (2000) (Pubitemid 30030671)
125. C. S. Cobbs, T. R. Whisenhunt, D. R. Wesemann, L. E. Harkins, E. G. Van Meir and M. Samanta: Inactivation of wild-Type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res, 63(24), 8670-3 (2003) (Pubitemid 38064042)
126. S. A. Kusmartsev, Y. Li and S. H. Chen: Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol, 165(2), 779-85 (2000) (Pubitemid 30484744)
127. E. M. Hanson, V. K. Clements, P. Sinha, D. Ilkovitch and S. Ostrand-Rosenberg: Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol, 183(2), 937-44 (2009)
128. V. Bronte and P. Zanovello: Regulation of immune responses by L-Arginine metabolism. Nat Rev Immunol, 5(8), 641-54 (2005) (Pubitemid 41113195)
129. M. Munder: Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol, 158(3), 638-51 (2009)
130. M. Munder, K. Eichmann, J. M. Moran, F. Centeno, G. Soler and M. Modolell: Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol, 163(7), 3771-7 (1999) (Pubitemid 29450901)
131. M. Munder, K. Eichmann and M. Modolell: Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol, 160(11), 5347-54 (1998) (Pubitemid 28267823)
132. V. Boutard, R. Havouis, B. Fouqueray, C. Philippe, J. P. Moulinoux and L. Baud: Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol, 155(4), 2077-84 (1995)
133. M. M. Jost, E. Ninci, B. Meder, C. Kempf, N. Van Royen, J. Hua, B. Berger, I. Hoefer, M. Modolell and I. Buschmann: Divergent effects of GM-CSF and TGFbeta1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: a potential role during arteriogenesis. Faseb J, 17(15), 2281-3 (2003) (Pubitemid 39561466)
134. M. Baniyash: TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol, 4(9), 675-87 (2004) (Pubitemid 39223074)
135. P. C. Rodriguez, A. H. Zea, K. S. Culotta, J. Zabaleta, J. B. Ochoa and A. C. Ochoa: Regulation of T cell receptor CD3zeta chain expression by L-Arginine. J Biol Chem, 277(24), 21123-9 (2002)
136. P. C. Rodriguez, D. G. Quiceno and A. C. Ochoa: L-Arginine availability regulates T-lymphocyte cellcycle progression. Blood, 109(4), 1568-73 (2007) (Pubitemid 46239590)
137. H. Kleinert, A. Pautz, K. Linker and P. M. Schwarz: Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol, 500(1-3), 255-66 (2004) (Pubitemid 39304013)
138. R. W. Ganster, B. S. Taylor, L. Shao and D. A. Geller: Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NFkappa B. Proc Natl Acad Sci U S A, 98(15), 8638-43 (2001) (Pubitemid 32678080)
139. I. Angulo, F. G. de las Heras, J. F. Garcia-Bustos, D. Gargallo, M. A. Munoz-Fernandez and M. Fresno: Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+) CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-Treated mice: implications for T-cell responses in immunosuppressed mice. Blood, 95(1), 212-20 (2000) (Pubitemid 30017245)
140. I. Angulo, R. Rodriguez, B. Garcia, M. Medina, J. Navarro and J. L. Subiza: Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-gamma. J Immunol, 155(1), 15-26 (1995)
141. I. Angulo, J. Rullas, J. A. Campillo, E. Obregon, A. Heath, M. Howard, M. A. Munoz-Fernandez and J. L. Subiza: Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-gamma stimulation through a mechanism dependent on endogenous TNF-Alpha and IL-1alpha. Eur J Immunol, 30(5), 1263-71 (2000) (Pubitemid 30311954)
142. T. A. Fischer, A. Palmetshofer, S. Gambaryan, E. Butt, C. Jassoy, U. Walter, S. Sopper and S. M. Lohmann: Activation of cGMP-dependent protein kinase Ibeta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells. J Biol Chem, 276(8), 5967-74 (2001)
143. R. M. Bingisser, P. A. Tilbrook, P. G. Holt and U. R. Kees: Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol, 160(12), 5729-34 (1998) (Pubitemid 28298028)
144. U. Eriksson, U. Egermann, M. P. Bihl, F. Gambazzi, M. Tamm, P. G. Holt and R. M. Bingisser: Human bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. J Immunol, 175(4), 2715-20 (2005) (Pubitemid 41113888)
145. A. Mazzoni, V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello and D. M. Segal: Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol, 168(2), 689-95 (2002) (Pubitemid 34049569)
146. S. E. Macphail, C. A. Gibney, B. M. Brooks, C. G. Booth, B. F. Flanagan and J. W. Coleman: Nitric oxide regulation of human peripheral blood mononuclear cells: critical time dependence and selectivity for cytokine versus chemokine expression. J Immunol, 171(9), 4809-15 (2003) (Pubitemid 37310601)
147. O. Harari and J. K. Liao: Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des, 10(8), 893-8 (2004) (Pubitemid 38380067)
148. L. Rivoltini, M. Carrabba, V. Huber, C. Castelli, L. Novellino, P. Dalerba, R. Mortarini, G. Arancia, A. Anichini, S. Fais and G. Parmiani: Immunity to cancer: attack and escape in T lymphocyte-Tumor cell interaction. Immunol Rev, 188, 97-113 (2002) (Pubitemid 35398868)
149. L. Santucci, J. Wallace, A. Mencarelli, S. Farneti, A. Morelli and S. Fiorucci: Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitis. Gastroenterology, 128(5), 1243-57 (2005) (Pubitemid 40712176)
150. C. Brito, M. Naviliat, A. C. Tiscornia, F. Vuillier, G. Gualco, G. Dighiero, R. Radi and A. M. Cayota: Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol, 162(6), 3356-66 (1999) (Pubitemid 29313585)
151. N. Moulian, F. Truffault, Y. M. Gaudry-Talarmain, A. Serraf and S. Berrih-Aknin: In vivo and in vitro apoptosis of human thymocytes are associated with nitrotyrosine formation. Blood, 97(11), 3521-30 (2001)
152. V. Bronte, T. Kasic, G. Gri, K. Gallana, G. Borsellino, I. Marigo, L. Battistini, M. Iafrate, T. Prayer-Galetti, F. Pagano and A. Viola: Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med, 201(8), 1257-68 (2005) (Pubitemid 40629069)
153. V. De Wilde, N. Van Rompaey, M. Hill, J. F. Lebrun, P. Lemaitre, F. Lhomme, C. Kubjak, B. Vokaer, G. Oldenhove, L. M. Charbonnier, M. C. Cuturi, M. Goldman and A. Le Moine: Endotoxin-induced myeloidderived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am J Transplant, 9(9), 2034-47 (2009)
154. G. A. Ricchetti, L. M. Williams and B. M. Foxwell: Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. J Leukoc Biol, 76(3), 719-26 (2004) (Pubitemid 39129106)
155. C. Chauveau, S. Remy, P. J. Royer, M. Hill, S. Tanguy-Royer, F. X. Hubert, L. Tesson, R. Brion, G. Beriou, M. Gregoire, R. Josien, M. C. Cuturi and I. Anegon: Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood, 106(5), 1694-702 (2005) (Pubitemid 41208583)
156. T. S. Lee and L. Y. Chau: Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med, 8(3), 240-6 (2002)
157. A. E. Loercher, M. A. Nash, J. J. Kavanagh, C. D. Platsoucas and R. S. Freedman: Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol, 163(11), 6251-60 (1999)
158. P. Sinha, V. K. Clements, S. K. Bunt, S. M. Albelda and S. Ostrand-Rosenberg: Cross-Talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. Journal of Immunology, 179(2), 977-83 (2007)
159. S. K. Bunt, V. K. Clements, E. M. Hanson, P. Sinha and S. Ostrand-Rosenberg: Inflammation enhances myeloidderived suppressor cell cross-Talk by signaling through Tolllike receptor 4. J Leukoc Biol, 85(6), 996-1004 (2009)
160. M. K. Srivastava, P. Sinha, V. K. Clements, P. Rodriguez and S. Ostrand-Rosenberg: Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res, 70(1), 68-77 (2010)
161. M. A. Mansoor, A. M. Svardal and P. M. Ueland: Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem, 200(2), 218-29 (1992)
162. I. Ishii, N. Akahoshi, X. N. Yu, Y. Kobayashi, K. Namekata, G. Komaki and H. Kimura: Murine cystathionine gamma-lyase: complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem J, 381(Pt 1), 113-23 (2004) (Pubitemid 38932217)
163. P. W. Gout, A. R. Buckley, C. R. Simms and N. Bruchovsky: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. Leukemia, 15(10), 1633-40 (2001) (Pubitemid 32994684)
164. H. Gmunder, H. P. Eck and W. Droge: Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones. Eur J Biochem, 201(1), 113-7 (1991)
165. H. Eagle, C. Washington and S. M. Friedman: The synthesis of homocystine, cystathionine, and cystine by cultured diploid and heteroploid human cells. Proc Natl Acad Sci U S A, 56(1), 156-63 (1966)
166. H. Gmunder, H. P. Eck, B. Benninghoff, S. Roth and W. Droge: Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine. Cell Immunol, 129(1), 32-46 (1990) (Pubitemid 20233611)
167. H. Sato, H. Watanabe, T. Ishii and S. Bannai: Neutral amino acid transport in mouse peritoneal macrophages. J Biol Chem, 262(27), 13015-9 (1987)
168. G. Angelini, S. Gardella, M. Ardy, M. R. Ciriolo, G. Filomeni, G. Di Trapani, F. Clarke, R. Sitia and A. Rubartelli: Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A, 99(3), 1491-6 (2002) (Pubitemid 34136520)
169. P. Castellani, G. Angelini, L. Delfino, A. Matucci and A. Rubartelli: The thiol redox state of lymphoid organs is modified by immunization: role of different immune cell populations. Eur J Immunol, 38(9), 2419-25 (2008)
170. H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, V. A. Lennon, E. Celis and L. Chen: Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.[see comment][erratum appears in Nat Med 2002 Sep;8(9):1039]. Nature Medicine, 8(8), 793-800 (2002)
171. H. Li, Y. Han, Q. Guo, M. Zhang and X. Cao: Cancerexpanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol, 182(1), 240-9 (2009)
172. B. Hoechst, T. Voigtlaender, L. Ormandy, J. Gamrekelashvili, F. Zhao, H. Wedemeyer, F. Lehner, M. P. Manns, T. F. Greten and F. Korangy: Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 50(3), 799-807 (2009)
173. N. Nausch, I. E. Galani, E. Schlecker and A. Cerwenka: Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood, 112(10), 4080-9 (2008)
174. J. S. Ko, A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, R. Dreicer, R. Bukowski and J. H. Finke: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical Cancer Research, 15(6), 2148-57 (2009)
175. S. J. Priceman, J. L. Sung, Z. Shaposhnik, J. B. Burton, A. X. Torres-Collado, D. L. Moughon, M. Johnson, A. J. Lusis, D. A. Cohen, M. L. Iruela-Arispe and L. Wu: Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of anti-Angiogenic therapy. Blood (2009)
176. H. van Cruijsen, A. A. van der Veldt, L. Vroling, D. Oosterhoff, H. J. Broxterman, R. J. Scheper, G. Giaccone, J. B. Haanen, A. J. van Den Eertwegh, E. Boven, K. Hoekman and T. D. de Gruijl: Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clinical Cancer Research, 14(18), 5884-92 (2008)
177. I. Fricke, N. Mirza, J. Dupont, C. Lockhart, A. Jackson, J. H. Lee, J. A. Sosman and D. I. Gabrilovich: Vascular endothelial growth factor-Trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res, 13(16), 4840-8 (2007) (Pubitemid 47298146)
178. S. Kusmartsev, E. Eruslanov, H. Kubler, T. Tseng, Y. Sakai, Z. Su, S. Kaliberov, A. Heiser, C. Rosser, P. Dahm, D. Siemann and J. Vieweg: Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol, 181(1), 346-53 (2008)
179. L. M. Coussens, B. Fingleton and L. M. Matrisian: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295(5564), 2387-92 (2002) (Pubitemid 34270240)
180. C. M. Overall and O. Kleifeld: Tumour microenvironment -opinion: validating matrix metalloproteinases as drug targets and anti-Targets for cancer therapy. Nature Reviews. Cancer, 6(3), 227-39 (2006) (Pubitemid 43292566)
181. E. Giraudo, M. Inoue and D. Hanahan: An aminobisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. Journal of Clinical Investigation, 114(5), 623-33 (2004) (Pubitemid 39578752)
182. C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb and M. P. Colombo: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67(23), 11438-46 (2007) (Pubitemid 350248572)
183. D. R. t. Coleman, Z. Ren, P. K. Mandal, A. G. Cameron, G. A. Dyer, S. Muranjan, M. Campbell, X. Chen and J. S. McMurray: Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-Affinity peptide inhibitor. Journal of Medicinal Chemistry, 48(21), 6661-70 (2005)
184. H. Song, R. Wang, S. Wang and J. Lin: A lowmolecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 102(13), 4700-5 (2005) (Pubitemid 40471517)
185. E. A. Nelson, S. R. Walker, A. Kepich, L. B. Gashin, T. Hideshima, H. Ikeda, D. Chauhan, K. C. Anderson and D. A. Frank: Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood, 112(13), 5095-102 (2008)
186. T. Kuwata, I. M. Wang, T. Tamura, R. M. Ponnamperuma, R. Levine, K. L. Holmes, H. C. Morse, L. M. De Luca and K. Ozato: Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood, 95(11), 3349-56 (2000) (Pubitemid 30428463)
187. C. R. Walkley, Y. D. Yuan, R. A. Chandraratna and G. A. McArthur: Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis. Leukemia, 16(9), 1763-72 (2002)
188. S. Kusmartsev, F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush and D. Gabrilovich: All-Trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research, 63(15), 4441-9 (2003) (Pubitemid 36951016)
189. N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia and D. I. Gabrilovich: All-Trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Research, 66(18), 9299-307 (2006) (Pubitemid 44521152)
190. D. M. Lathers, J. I. Clark, N. J. Achille and M. R. Young: Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunology, Immunotherapy, 53(5), 422-30 (2004) (Pubitemid 38657255)
191. R. F. Guo and P. A. Ward: Role of C5a in inflammatory responses. Annual Review of Immunology, 23, 821-52 (2005) (Pubitemid 40563186)
192. M. M. Markiewski, R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos and J. D. Lambris: Modulation of the antitumor immune response by complement. Nature Immunology, 9(11), 1225-35 (2008)
193. J. Davis: Eculizumab. American Journal of Health-System Pharmacy, 65(17), 1609-15 (2008)
194. L. Yang, J. Huang, X. Ren, A. E. Gorska, A. Chytil, M. Aakre, D. P. Carbone, L. M. Matrisian, A. Richmond, P. C. Lin and H. L. Moses: Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13(1), 23-35 (2008) (Pubitemid 350309741)
195. B. Huang, Z. Lei, J. Zhao, W. Gong, J. Liu, Z. Chen, Y. Liu, D. Li, Y. Yuan, G. M. Zhang and Z. H. Feng: CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Letters, 252(1), 86-92 (2007) (Pubitemid 46734559)
196. R. A. Wilcox, D. A. Wada, S. C. Ziesmer, S. F. Elsawa, N. I. Comfere, A. B. Dietz, A. J. Novak, T. E. Witzig, A. L. Feldman, M. R. Pittelkow and S. M. Ansell: Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood, 114(14), 2936-44 (2009)
197. C. Napoli, E. Ackah, F. De Nigris, P. Del Soldato, F. P. D'Armiento, E. Crimi, M. Condorelli and W. C. Sessa: Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proceedings of the National Academy of Sciences of the United States of America, 99(19), 12467-70 (2002)
198. S. Mariotto, L. Cuzzolin, A. Adami, P. Del Soldato, H. Suzuki and G. Benoni: Effect of a new non-steroidal antiinflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. British Journal of Pharmacology, 115(2), 225-6 (1995)
199. S. Mariotto, L. Cuzzolin, A. Adami, P. Del Soldato, H. Suzuki and G. Benoni: Inhibition by sodium nitroprusside of the expression of inducible nitric oxide synthase in rat neutrophils. British Journal of Pharmacology, 114(6), 1105-6 (1995)
200. C. De Santo, P. Serafini, I. Marigo, L. Dolcetti, M. Bolla, P. Del Soldato, C. Melani, C. Guiducci, M. P. Colombo, M. Iezzi, P. Musiani, P. Zanovello and V. Bronte: Nitroaspirin corrects immune dysfunction in tumorbearing hosts and promotes tumor eradication by cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America, 102(11), 4185-90 (2005) (Pubitemid 40388577)
201. L. Zitvogel, L. Apetoh, F. Ghiringhelli and G. Kroemer: Immunological aspects of cancer chemotherapy. Nat Rev Immunol, 8(1), 59-73 (2008)
202. E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser and S. M. Albelda: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research, 11(18), 6713-21 (2005)
203. H. K. Le, L. Graham, E. Cha, J. K. Morales, M. H. Manjili and H. D. Bear: Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. International Immunopharmacology, 9(7-8), 900-9 (2009)
204. R. A. Wilcox, W. K. Nevala, M. A. Thompson, T. E. Witzig, S. M. Ansell and S. N. Markovic: CD14+ HLADR-/ Lo Myeloid-Derived Suppressor Cells Express Immunosuppressive B7-H Family Members and Are Depleted Following Taxane-Based Chemotherapy in Melanoma. Blood, 114: 464. (2009)
205. F. Shojaei, X. Wu, X. Qu, M. Kowanetz, L. Yu, M. Tan, Y. G. Meng and N. Ferrara: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 106(16), 6742-7 (2009)
206. F. Shojaei and N. Ferrara: Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Research, 68(14), 5501-4 (2008)
207. F. Shojaei, M. Singh, J. D. Thompson and N. Ferrara: Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 105(7), 2640-5 (2008) (Pubitemid 351520566)
208. F. Shojaei, X. Wu, C. Zhong, L. Yu, X. H. Liang, J. Yao, D. Blanchard, C. Bais, F. V. Peale, N. van Bruggen, C. Ho, J. Ross, M. Tan, R. A. Carano, Y. G. Meng and N. Ferrara: Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature, 450(7171), 825-31 (2007) (Pubitemid 350231321)
209. J. LeCouter, C. Zlot, M. Tejada, F. Peale and N. Ferrara: Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proceedings of the National Academy of Sciences of the United States of America, 101(48), 16813-8 (2004)
210. F. Shojaei, X. Wu, A. K. Malik, C. Zhong, M. E. Baldwin, S. Schanz, G. Fuh, H. P. Gerber and N. Ferrara: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol, 25(8), 911-20 (2007) (Pubitemid 47236916)
211. S. Nagaraj, M. Collazo, C. A. Corzo, J. I. Youn, M. Ortiz, D. Quiceno and D. I. Gabrilovich: Regulatory myeloid suppressor cells in health and disease. Cancer Res, 69(19), 7503-6 (2009)